Log In
BCIQ
Print this Print this
 

LixiLan, Lixisenatide/insulin glargine

Also known as: Lixisenatide/ZP10+Lantus

  Manage Alerts
Collapse Summary General Information
Company Zealand Pharma A/S
DescriptionCombination of Lyxumia lixisenatide/ZP10 and Lantus insulin glargine
Molecular Target Glucagon-like peptide-1 receptor (GLP-1R) (GLP1R) ; Insulin receptor (INSR)
Mechanism of ActionGlucagon-like peptide-1 (GLP-1) receptor agonist; Insulin receptor agonist
Therapeutic ModalityPeptide
Latest Stage of DevelopmentRegistration
Standard IndicationDiabetes
Indication DetailsTreat Type II diabetes
Regulatory Designation
PartnerSanofi

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today